Andy in Therapeutics' call morning, and after Dr. On Medical order welcome Einhorn to XXXX's Tony and earnings Officer, Head in I Interim our you, Daniel. results. everyone be Chief Caggiano, and share R&D company's will which performance of Officer questions. your XXXX, remarks and Financial the Thank on Chief our prepared progress conference Good we'll to financial today's call, covering take joined Cognition by
Cognition proud I will We am an is XXXX. the anticipate exciting the time at has It momentum Therapeutics, built. this momentum continue company and into of
believe working field this Looking back, of clinical of I and a in in of have a sense us year scientific the neurodegeneration. many optimism in first the all years. arena what well-deserved time for
testament LEQEMBI, Alzheimer's that progress saw patients, together With on. many the biopharmaceutical with industry market to agencies build of product bring professionals, will Alzheimer's the medical a to true disease slow of can that approval community This a serves progression. us the as regulatory
we Cognition, and lead paradigm candidate to At therapies believe our part commitment of are the treatment unwavering dementia that these conditions. to for CTXXXX, our has important an we develop in evolving our to advance potential the work be for
many As on degenerative of our of innovative, and development of candidates know, the orally the is primary available age drug the related diseases focus you retina. CNS targeting
Our disrupted of current upon which result expertise that σ-X are programs number biology, with a regulates a neurodegenerative of clinical company's cellular as the receptor build functions disease.
the DLB clinic Alzheimer's dementia bodies disease refer Lewy with in as being currently is tested or candidate it. drug Our to for we and
we as with disease. patients both patients stage mild Within Alzheimer's as to [sending] disease, are well early moderate (ph)
in a Modulating unique neurodegenerative commonly disease drug a is molecule complex as new In CTXXXX now dry approaches referred the both with indication, in generation, optimology as related addition, age receptor a and brain well studying macular as we're differentiated space. σ-X small to and disease well penetrant atrophy, to in the geographic AMD. from secondary retinal approach dry candidate
waves disease tied study. anticipated II In our for completed sequence for Alzheimer's to on each memory the update clinical and processing we're timelines me relative of our mild this Phase to study data demonstrates measuring decreasing enrollment the and dose once moderate let EEG Now brief information. we We CTXXXX role toxicity anticipate provide trial brain hope February, patterns power a trials top of of oligomers, state a by SEQUEL synapses in we reporting daily XXXX. of will normalize placebo, Aβ from of later further line from CTXXXX to in where can protecting that support the
and Supported been by patient Republic SHINE disease the on approximately the dosed. patients expanded are currently where $XX the National our being totaling internationally moderate multiple for Institute grants to XXX to has Aging, trial X from mild Spain, million Phase Netherlands Czech
to We running. grateful for sites partners our diligence their up and are in getting
led Jim treatment a to is grant options. trial. Galvin University the moderate expected Phase based people estimated to $XX no conducted The whom NIA affected sites at which from patients being is be supported X.X than by with dementia Dr. is Miami more of An is which million CTXXXX, of by also non-dilutive study for Lewy DLB, enrolling from X U.S. United million study the the all have SHIMMER bodies a across by States. mild Our XX with in are
expect We data year. shimmer from next
who forces our in partner, for early CTXXXX START subjects are With grant proposed with to Alzheimer's on, on enroll patients. measure regulatory trials START immense to join site clinical Phase with We have protocol our impairment ACTC. expect with this trial Alzheimer's our clearance are tolerability pleased disease in preparing an consortium, we mild patient XXX work to trial and disease. levels. efficacy Aβ we trial received million patients elevated protocol, XXXX. or on the We will begin $XX totaling the in cognitive for and early Moving activations Alzheimer's the of received with the that and is is the X FDA In clearance our collaboration
that atrophy, ARVO with and the area an treatments for we frustrated for failed AMD challenges geographic indications, has dry AMD for the in ophthalmology with to presented supports geographic community many concept to CTXXXX the and Shifting ophthalmic decades AMD, of opportunity proof dry atrophy, somewhat that the dry to the Dry secondary data known can loss. connection paralleling atrophy dementia, is conference is for developing develop population The atrophy a lead to age in unmet need geographic AMD An XX% to estimated estimated related progressive in the up geographic treatments. for have advanced degeneration. of million area permanent X substantial with for making as vision and account macular U.S. of market. a people the attempts effective vital to to form
seeing it AMD major recent adding from in education we the groundbreaking With surge cause pipeline time and physician to approval a as to around of [Applause] Pharmaceutical, (ph) be [indiscernible] an this is are blindness. patient dry of exciting our
that our wide dry beneficial evidence may at opportunity, the Looking have study of Alzheimer's as with well a CTXXXX demonstrate on treatment AMD. proteins we studies genome implicated from impact analyses have as results our from in
geographic AMD to Phase trial, As to which measurable XXX diagnosed year, who've X a received randomized recently announced, expected AMD plan the a it, people atrophy. trial, as MAGNIFY we we've trial we commence placebo clearance Phase X to geographic this initiate is enroll we been and controlled FDA atrophy dry dry call approximately with
that loss. in treatment acuity, lesion efficacy assess low size measures geographic the to as and be visual period, well atrophy, Over corrected best will and in determined change other vision of CTXXXX as safety
our closing, made. clinical In progress have and am the scientific proud I of teams
neuroscience vital this into -- podcast scientific order We're Cognition service it and and leaders to with to arena and and community, Conversations is reach investment latest that various The are new an patient the the centric thought closer including expanding that we expanding of have launched we're about and as was to podcast. we doing work information educate ability public optimistic expand community, and the mindset, the mission. provide important patients. regions to indications. us decided Our patients serve continue our In to audiences our medical about trials caregivers the our the that communicate in moving extend functions we developments research. With are clearinghouse world to we benefiting messages
what team diligent be in To believe will sets XXXX XXXX. rich we for summarize, the the stage our milestone a work of
Looking neurodegenerative creating full the diseases to CNS NASDAQ, believe publicly a of and we of on and I our the the as our tools company retina. mission back therapies have the for first of continue year resources age related on listed operating
turn With to Andy. that, I call the
